January 6, 2022 – San Clemente, Calif. Smiths Medical has been acquired by ICU Medical Inc. (NASDAQ: ICUI) (LSE: SMIN.L). Smiths Medical’s portfolio of products includes syringe and ambulatory infusion devices, vascular access, and critical care. When united with ICU Medical’s current operations, the combined firms establish a market-leading infusion treatment enterprise with roughly $2.5 billion in pro forma combined sales.
“We are thrilled that Smiths Medical has become a part of ICU Medical, and we would like to extend a warm welcome to our new Smiths colleagues.” We look forward to collaborating to ensure that ICU Medical continues to provide quality, innovation, and value to its clinical clients globally,” stated Vivek Jain, chairman and CEO of ICU Medical. “The acquisition of Smiths Medical complements ICU Medical’s current business and establishes a scaled global rival headquartered in the United States that strengthens the medical supply chain and has the potential to expand as clinical care models develop.”
The transaction capitalizes on considerable investment in integration and infrastructure created to support the 2017 acquisition of Hospira Infusion Systems. It will enable ICU Medical to expand on a business culture that values responsibility, openness, swift and informed decision-making, and a commitment to addressing client demands.
On its Q4 earnings call in late February, the business aims to provide detailed FY 2022 forecast.
